# A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

> **NCT05126758** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Capricor Inc.** · enrollment: 106 (actual)

## Conditions studied

- Muscular Dystrophies
- Muscular Dystrophy, Duchenne
- Muscular Disorders, Atrophic
- Muscular Diseases
- Neuromuscular Diseases
- Genetic Diseases, X-Linked
- Genetic Diseases, Inborn
- Nervous System Diseases

## Interventions

- **BIOLOGICAL:** Deramiocel (CAP-1002)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05126758
- **Lead sponsor:** Capricor Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-22
- **Primary completion:** 2025-06-18
- **Final completion:** 2026-12
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05126758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05126758, "A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05126758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*